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The potential advantages of local excision for rectal cancer are clear and include
minimal morbidity and preservation of anorectal, urinary, and sexual functions.
Conventional full-thickness transanal excision has been recommended as the
definitive treatment of early rectal cancer, but there have been growing number of
concerns and contradictory results regarding the efficacy of local surgery. Many
studies have now verified that recurrence after local excision of early rectal
cancers is significantly higher than expected.1-4 Furthermore, recurrence after local
surgery is generally characterized by advanced disease and poor long-term survival.1,5
We recently reported that local excision after neoadjuvant therapy could
probably be an acceptable alternative to conventional radical surgery in selected
patients with rectal cancer.6 Those results prompted us to review our experience of
transanal excision in patients with rectal cancer. The purpose of this study was to
evaluate the long-term oncologic results of transanal local excision for early rectal
adenocarcinomas and review the outcomes of salvage therapy.
We reviewed the records of 54 consecutive patients who were treated by local
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Purpose: The role of local excision in treating rectal cancer patients continues to be controversial. The aim of this
study was to evaluate the long-term oncological results of local excision for early rectal adenocarcinomas and
review the outcomes of salvage therapy on rectal cancer patients. Materials and Methods: Between March 1992
and September 2005, 35 consecutive patients with early-stage primary rectal adenocarcinomas were treated by local
excision with curative intent. The mean tumor distance from the anal verge was 5 cm (range, 1-10 cm). Results:
The median follow-up was 66 months (range, 17-161 months). Pathological examination revealed 23 cases of T1
and 12 cases of T2. Recurrence had developed in 10 patients (6 local recurrences, 4 systemic recurrences). Purely
extrapelvic recurrence was observed in only two (5.7%) patients. Of the eight recurrent patients with surgical
salvage, five survived with no evidence of disease at the time of this analysis. The 5-year local recurrence-free and
disease-free survival rates were 79.6% and 67.9%, respectively. Conclusion: Local excision alone of early-staged
rectal adenocarcinomas, even in the ideal candidate, is followed by a relatively higher local recurrence rate than
previously reported and may not be a valid modality. Either the use of adjuvant therapy with local excision, even in
patients with T1 lesions or the use of preoperative therapy followed by local excision has good promise.
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INTRODUCTION
MATERIALS AND METHODS
therapy for rectal cancer at the Gangnam Severance
Hospital and Yonsei University Health System between
March 1992 and September 2005. Thirty-five patients with
pathologic diagnoses of primary T1 or T2 adenocarcinoma
of the rectum who had undergone definitive treatment by
full-thickness transanal local excision were included in this
study. The following were the criteria for patient selection:
a mobile tumor, occupying less than one-third of the rectal
circumference, well to moderately differentiated, and stage
T1-2 on endorectal ultrasonography (ERUS). Nineteen
cases were excluded from analysis for the following
reasons: laser fulguration (n = 4), stage IV cancer (n = 4),
recurred cancer (n = 1), preoperative chemoradiation (n =
9), and follow-up loss (n = 1).
The details of our transanal local excision experience
have been previously published.6 Pretreatment assessment
included routine physical examination, chest radiography,
rigid proctoscopy, colonoscopy, abdominopelvic computed
tomography (CT), ERUS, and measurement of serum
carcinoembryonic antigen (CEA) levels. Tumor staging
was established by considering the combined results of all
modalities used. ERUS was performed on all 35 patients,
and 21 of their lesions were staged as uT1N0, 13 as uT2N0,
and 1 as uT0N0. All tumors were removed by transanal
local excision. The lesions were removed using electrocau-
tery to perform a full-thickness excision with approxima-
tely a 1-cm margin of normal rectal wall. Two cases of
transanal endoscopic microsurgery were included in this
analysis.
Patients were followed at 3-month intervals during the
first two postoperative years, biannually until the fifth
postoperative year, and annually thereafter. At each visit,
we took a medical history, measured serum CEA levels,
and performed a physical examination (including rectal
examination). Additional follow-up examinations includ-
ing chest X-ray, abdomino-pelvic CT, colonoscopy, and
positron emission tomography (PET) scanning were per-
formed on a semiannual basis during the first two post-
operative years and then annually, as well as when there
was a suspicion of recurrence. Local recurrence was defined
as recurrence within the pelvis; and systemic recurrence
was defined as disease outside of the pelvis. The main
patterns of recurrence were recorded as the first site of
detectable failure during the follow-up period. If the patient
did not return for observation after one year, the necessary
information was obtained by letter or telephone.
Statistical evaluation was performed using the statistical
package SPSS for Windows (version 12.0, SPSS Inc.,
Chicago, IL, USA). Differences between the two groups
were tested using the Student’s t-test and chi-squared test
when appropriate. Kaplan-Meier methodology was used to
estimate overall survival, disease-free survival, and local
recurrence rates; and the log-rank test was used to assess
statistical significance. A value of p < 0.05 was considered
statistically significant.
The patient and tumor characteristics for all 35 patients are
summarized in Table 1. Patients undergoing transanal
excision had a mean tumor diameter of 2.2 cm (range, 1 - 5
cm) and a mean distance from the anal verge of 5.2 cm
(range, 1-10 cm). Pathology review confirmed 23 T1
cancers and 12 T2 cancers. All tumors proved to have
well-differentiated or moderately-differentiated histology,
and there was no case of poorly differentiated or mucinous
cancer. There was no evidence of lymphovascular invasion
in any case. After transanal excision, two patients with
microscopic involvement of the surgical margins received
adjuvant radiotherapy due to either the significant medical
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Table 1. Patient Characteristics (n = 35)
Values
Mean age (yr) 58 (30 - 83)
Male/Female 17 / 18
Body mass index (kg/m2) 23.6 ± 3.7
ASA score
I 18 (51.4)
II 13 (37.2)
III 4 (11.4)
Mean tumor diameter (cm) 2.2  ± 1.0 (1 - 5)
Mean distance from anal 
5.2 ± 2.5 (1 - 10)
verge (cm)
Tumor location
Anterior 8 (22.9)
Lateral 9 (25.7)
Posterior 18 (51.4)
Pathologic T-staging
pT1 23 (65.7)
pT2 12 (34.3)
Histology
Well differentiated 16 (45.7)
Moderate differentiated 19 (54.3)
Positive lymphovascular invasion None
Positive surgical margins* 2 (5.7)
Preoperative serum CEA 
3.3 ± 5.0 (0.2 - 28.9)
(ng/mL)
Postoperative serum CEA 
1.9  ± 1.2 (0.1 - 5.6)
(ng/mL)
ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen.
*Tumor extending to the surgical resection margin (≤ 1 mm).
RESULTS
comorbidity or absolute refusal of a permanent stoma by
the patient.
After a median follow-up of 66 months (range, 17-161
months), recurrence was identified in 10 of 35 patients
(28.5%). There was no perioperative mortality. The
patterns of recurrence, treatment modalities used, and
outcome with follow up are shown in Table 2. Local
recurrence occurred in 6 patients (17.1%), of whom 5 were
T1 and 1 was T2. Two patients (one in T1 and one in T2)
had distant metastasis alone (5.7%), and the other two
patients (both T2) had distant and local recurrence (5.7%).
All metastases were found in the lung, and there was no
case of hepatic or peritoneal metastasis. The median
recurrence time for the 10 observed recurrences was 29
months (range, 4-48 months).
During the follow-up period, there were 8 deaths among
the 35 patients. Of these, four died from causes related to
cancer recurrence. Seventy-one percent of the T1 patients
and 64.8% of the T2 patients were alive with no evidence
of disease (Fig. 1). Overall 5-year survival rates were 93.3%
and 64.9% for patients with T1 and T2 tumors respectively
(Fig. 2). Two of ten patients with recurrent disease received
palliative treatment. These two patients had unresectable
lung metastases: one received chemotherapy only and the
other underwent additional low anterior resection due to
obstruction. Both died of their disease. Of the eight recur-
rent patients with curative surgeries, two died of disease
and five were alive with no clinical evidence of recurrent
disease at the time of this report. One patient who under-
went lung resection was alive despite an additional recur-
rence that occurred 14 months after salvage surgery. Two
patients who received postoperative radiation therapy due
to positive resection margins were alive at 42.5 and 45.6
months after surgery with no evidence of disease.
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Table 2. Patients with Recurrence after Transanal Excision (n = 10)
Initial Type of
RFS (mo) Salvage therapy Recurred pT
Follow-up 
Remarks
pT recurrence (mo)
M 57 T1 Rectum 4 Reexcision T2 48 Alive
M 64 T1 Rectum 48 LAR T3 24 Alive
M 58 T1 Lung 35 Lung resection - 31 Alive with disease
M 50 T1 Mesorectum 14 LAR - 42 Alive
F 68 T2 Lung 23 Chemotherapy only-P* - 28 Dead
F 64 T2 Rectum, lung 38 LAR-P* T3 16 Dead
F 68 T2 Rectum 6
Neoadjuvant chemoradiation 
CR 86 Alive
followed by reexcicion
M 45 T1 Pelvic node 44 LAR - 73 Alive
F 42 T1 Rectum 46 LAR T3 10 Dead
F 52 T2 Rectum, lung 15 Reexcision & lung resection T2 25 Dead
pT, pathologic T-staging; RFS, recurrence-free survival; LAR, low anterior resection; CR, complete remission.
*P = palliative.
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Fig. 1. Five-year disease free survival rates according to the depth of invasion (T).
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Fig. 2. Five-year overall survival rates according to the depth of invasion (T).
Cox proportional hazards models were used to study the
risk factors for recurrence. Gender, age, body mass index,
tumor size, location, distance from the anal verge, degree
of differentiation, tumor morphology, and preoperative
level of serum CEA were examined. None of these varia-
bles affected the rate of recurrence independently or in
combination with other factors.
The role of local excision in the treatment of early rectal
cancer continues to be controversial. Local surgery mini-
mizes both morbidity and bowel, bladder, and sexual
dysfunction. Local excision of rectal cancer has been
accepted for many years as an alternative to radical
resection for patients who are unfit to undergo major
abdominal surgery. Moreover, with appropriate selection
of patients with the lowest chance of recurrence, local
excision may be curative.7 Several studies that have demon-
strated satisfactory tumor control are heterogeneous in
study design, including selection criteria, use of adjuvant
therapy, and follow-up periods.8-11
Recent reports with long follow-up periods, however,
suggest that this approach is associated with higher-than-
expected recurrence rates for early rectal cancer.12-16 Fur-
thermore, the long-term outcome in patients undergoing
surgical salvage for recurrent disease appears to be worse
than expected.1,5,14 Taylor, et al.12 reported a 30% local
recurrence rate for T1 and T2 tumors treated by local
excision alone. Garcia-Aguilar, et al.13 found that 18% with
T1 tumors and 37% with T2 tumors had recurrence at 54
months of follow up. Madbouly, et al.14 reported a similar
overall recurrence rate of a 28.8% in T1 rectal cancers. In
the present study, with a median follow up of 66 months,
the overall recurrence rate was 28.5% in early rectal
tumors with favorable pathologic features, making our
results consistent with the most recent reports.12-16
Because of the relatively high rate of local recurrence
after local excision, the use of preoperative or postopera-
tive adjuvant therapy with local excision has been evaluated.
We recently reported nine highly-selected patients treated
with transanal excision after preoperative chemoradiation
for locally-advanced rectal cancer,6 and our observation
was that a combination of modality transanal excision and
preoperative chemoradiation represents an acceptable
alternative to conventional radical surgery. Some authors
suggest that local excision alone might not be sufficient
even for early rectal cancer, and that the potential combi-
nation of local excision and postoperative radiation may
facilitate good local control with a high survival rate.2,16,17 In
this study, two patients who received postoperative radio-
therapy were alive at 42.5 and 45.6 months after surgery
with no evidence of disease despite positive excision
margins. Our series did not include tumors with unfa-
vorable histologic features such as lymphovascular inva-
sion and poor differentiation of mucinous components,
except in the two patients with positive excision margins.
As a result, the recurrence rates should be lower than
reported in series that included unselected patients, never-
theless, we did not observe a lower rate of recurrence in
our patients. Interpretation was limited because of the
sample size, but we also believe that combining adjuvant
therapy and local excision may be a reasonable option to
improve oncological outcomes.
Rectal cancer is more likely than colon cancer to be
associated with lung metastases without liver metastases.18
The incidence of lung metastases in colorectal cancer
ranges from 10% to 20%, depending on the stage of
primary tumor.19,20 In our study, all four of the ten patients
who had systemic recurrences had pulmonary metastases.
This finding suggests a high incidence of lung metastases
in patients with local excision for lower rectal cancer.
However, there is little available evidence linking the loca-
tion of rectal cancer and the incidence of pulmonary
metastases.
Strict selection criteria are essential when considering
local excision, because more favorable outcomes will be
expected by proper selection of the patients.21,22 Bretagnol,
et al.23 suggested that local excision for cure may be consi-
dered in patients with a tumor with no adverse pathologic
features, including T1 sm3 or T2, Grades II-III differen-
tiated histology, and lymphovascular invasion. What is the
reason for the high local recurrence rates, especially in T1
cancer, in our study? One possible cause is the potential
high incidence of deep invasion (sm2 or sm3) in the T1
population. Advanced level of invasion is the well known
risk factor in recurrence, but a detailed pathologic evalua-
tion such as a grouping according to the level of invasion
(sm1, sm2, sm3) was not performed in this analysis. Our
study was a retrospective analysis of patients who under-
went local excision according to their pathology report.
There are limitations to any retrospective study, including
this one. A second possible cause of local failure is the
presence of occult, disseminated disease in regional
lymphatics. Landmann, et al.3 suggested that nodal disease
associated with early rectal lesions tends to be small in
size, is very easily missed on preoperative ERUS, and is
responsible for pelvic recurrence after local excision. In this
study, two of five local recurrences in T1 patients (1 meso-
rectal and 1 pelvic node recurrence) may be due to inac-
curate preoperative staging. Although our study is perhaps
not substantial enough to produce definite conclusions, it
may still allow us to make valid recommendations.
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DISCUSSION
Local excision alone of early-staged rectal adenocarci-
nomas, even in the ideal candidate, is followed by a
relatively higher local recurrence rate than previously
reported and may not be a valid modality. When consi-
dering local excision, patients should be informed of the
risk of local recurrence. Either the use of adjuvant therapy
with local excision, even in patients with T1 lesions, or the
use of preoperative therapy followed by local excision has
promise, but must be part of a prospective randomized
clinical trial before clearer guidelines can be drawn.
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